Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166081 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
A Phase 1 study of Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07166081: Recruiting Phase 1 study of Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co..
NCT07166081 is a Phase 1 study of Non-diabetic Overweight or Obese that is actively recruiting participants, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166081, a Phase 1 study of Non-diabetic Overweight or Obese, is actively recruiting participants, sponsored by BrightGene Bio-Medical Technology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Primary Outcome
The relationship of each adverse event tothe investigational product was assessed by the investigator
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BGM0504
Study Locations (1)
Maryland
- Pharmaron CPC, Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 1 |
What NCT07166081 shows while recruiting
NCT07166081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Non-diabetic Overweight or Obese appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07166081 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07166081 about?
NCT07166081 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects". This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult sub...
What is the current status of trial NCT07166081?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-08-11. Estimated completion is 2026-05-13.
What conditions does trial NCT07166081 study?
This clinical trial studies the following conditions: Non-diabetic Overweight or Obese.
What interventions are being tested in trial NCT07166081?
The interventions under investigation include: Placebo (DRUG), BGM0504 (DRUG).
Who is sponsoring clinical trial NCT07166081?
This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07166081 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07166081's enrollment target sits among peer trials
80 673rd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI